Pfizer Reports Strong Q1 Earnings, Reaffirms 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PFE?
Source: Newsfilter
- Earnings Beat: Pfizer's adjusted earnings per share for Q1 reached 75 cents, exceeding the expected 72 cents, reflecting strong performance in newly launched and acquired products, which bolsters investor confidence.
- Revenue Growth: The company reported Q1 revenue of $14.45 billion, surpassing Wall Street's expectation of $13.79 billion, indicating significant growth in its new product offerings and acquisitions, further solidifying its market position.
- Strategic Acquisition: Pfizer's recent $10 billion acquisition of obesity biotech Metsera aims to diversify its product line to offset declining COVID product sales, demonstrating the company's strategic focus on future growth.
- R&D Focus: Pfizer is prioritizing several key data releases this year, including late-stage trial results for an experimental targeted drug in lung cancer, which is expected to drive new growth opportunities for its product pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.330
Low
24.00
Averages
28.56
High
35.00
Current: 26.330
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Set to Report Earnings with Flat Revenue Expectations
- Earnings Preview: Pfizer is set to report earnings before the bell on Tuesday, with market expectations for flat revenue year-over-year, indicating a potential recovery from the 7.8% decline recorded in the same quarter last year.
- Revenue Performance: Last quarter, Pfizer reported revenues of $17.56 billion, down 1.2% year-over-year, which, while beating analyst expectations, showed a significant miss on organic revenue estimates, highlighting ongoing challenges for the company.
- Market Sentiment: Over the past month, Pfizer's stock has declined by 5.2%, contrasting sharply with peers like Eli Lilly and Merck, which reported revenue growth of 55.5% and 4.9%, respectively, indicating Pfizer's competitive disadvantages.
- Analyst Expectations: With an average analyst price target of $29.00 against a current share price of $26.38, there is a cautious outlook on Pfizer's future performance, especially as most analysts have revised their revenue estimates downward.
See More
PayPal and Anheuser-Busch Beat Earnings Expectations
- PayPal Earnings Surprise: PayPal reported first-quarter earnings of $1.34 per share, exceeding analyst expectations of $1.27, with revenues of $8.35 billion surpassing the $8.05 billion forecast, indicating strong performance in the payments sector that could drive stock price increases.
- Anheuser-Busch Strong Growth: Anheuser-Busch reported earnings of $0.97 per share, beating the expected $0.89, with revenues of $15.27 billion significantly above the $14.87 billion forecast, demonstrating sustained competitiveness in the beer market that may attract more investor interest.
- Pfizer Exceeds Expectations: Pfizer's first-quarter earnings came in at $0.75 per share, above the $0.72 expected, with revenues of $14.45 billion, reflecting robust growth in the pharmaceutical sector that could enhance market confidence in its future products.
- Pinterest Optimistic Revenue Guidance: Pinterest's second-quarter revenue guidance of $1.13 billion to $1.15 billion exceeded the $1.11 billion expected, with first-quarter adjusted earnings of $0.27 per share and revenues of $1.01 billion, showcasing strong growth potential in the social media space that is likely to improve market perceptions of its long-term value.
See More
Pfizer Q1 Earnings Exceed Expectations
- Strong Performance: Pfizer reported adjusted earnings per share of 75 cents for Q1, surpassing the expected 72 cents, with revenue of $14.45 billion reflecting a 5% year-over-year increase, demonstrating robust market performance driven by both new and established products.
- Growth in New Products: The company saw a 22% operational growth in recently launched and acquired products, with the targeted cancer drug Padcev generating $591 million in revenue, a 39% increase from the previous year, exceeding analyst expectations of $542.3 million, indicating a strong return on investment in innovative therapies.
- Decline in Vaccine Sales: Despite the Covid vaccine and Paxlovid generating only $232 million and $186 million in sales, down 59% and 62% year-over-year respectively, Pfizer offset this impact with strong performance from established drugs like Eliquis, which generated $2.17 billion, a 13% increase.
- Stable Long-term Outlook: Pfizer reaffirmed its 2026 outlook, expecting adjusted earnings per share between $2.80 and $3.00 and revenue between $59.5 billion and $62.5 billion, reflecting confidence in navigating challenges from declining Covid product sales and increased market competition.
See More
Pfizer Reports Strong Q1 Earnings, Reaffirms 2026 Outlook
- Earnings Beat: Pfizer's adjusted earnings per share for Q1 reached 75 cents, exceeding the expected 72 cents, reflecting strong performance in newly launched and acquired products, which bolsters investor confidence.
- Revenue Growth: The company reported Q1 revenue of $14.45 billion, surpassing Wall Street's expectation of $13.79 billion, indicating significant growth in its new product offerings and acquisitions, further solidifying its market position.
- Strategic Acquisition: Pfizer's recent $10 billion acquisition of obesity biotech Metsera aims to diversify its product line to offset declining COVID product sales, demonstrating the company's strategic focus on future growth.
- R&D Focus: Pfizer is prioritizing several key data releases this year, including late-stage trial results for an experimental targeted drug in lung cancer, which is expected to drive new growth opportunities for its product pipeline.
See More
BioNTech to Close Sites Affecting 1,860 Jobs and Buy Back $1 Billion in Shares
- Job Cuts and Site Closures: BioNTech announced the closure of multiple sites in Idar-Oberstein, Marburg, and Tuebingen in Germany, as well as in Singapore, affecting up to 1,860 jobs, reflecting a strategic shift following the transfer of COVID-19 vaccine production to partner Pfizer.
- Executive Departures Impact: The departure of the two co-founders and key executives by year-end to focus on new treatments may impact the company's innovation capacity and market competitiveness, particularly in the vaccine sector.
- Cost-Cutting Initiatives: BioNTech plans to implement gradual cost reductions, potentially achieving annual savings of about €500 million by 2029, aimed at improving financial health amid reported net losses.
- Share Buyback Program: The company announced a share buyback of up to $1 billion over the next 12 months to bolster shareholder confidence and enhance stock prices, despite reporting a net loss of €532 million in the first quarter, indicating current financial pressures.
See More
Pfizer's Q1 Earnings Outlook Shows Optimism
- Optimistic Earnings Outlook: Pfizer is expected to exceed market expectations in its Q1 earnings report, with analysts expressing optimism about its robust product pipeline, particularly in the obesity treatment sector, which could drive future revenue growth.
- Pipeline Potential Analysis: The progress in Pfizer's obesity pipeline has garnered attention, with analysts believing that success in this area will provide new revenue streams and further solidify the company's leadership position in the pharmaceutical industry.
- Positive Market Reaction: Investors are optimistic about Pfizer's prospects, anticipating that the company will leverage continuous innovation and strong R&D capabilities to navigate market challenges, thereby enhancing shareholder value.
- Guidance Focus: Pfizer will provide future performance guidance in its earnings report, and the market will closely monitor its outlook for overall performance in 2023 to assess the company's strategic positioning in the competitive pharmaceutical landscape.
See More
Pfizer Set to Report Earnings with Flat Revenue Expectations
- Earnings Preview: Pfizer is set to report earnings before the bell on Tuesday, with market expectations for flat revenue year-over-year, indicating a potential recovery from the 7.8% decline recorded in the same quarter last year.
- Revenue Performance: Last quarter, Pfizer reported revenues of $17.56 billion, down 1.2% year-over-year, which, while beating analyst expectations, showed a significant miss on organic revenue estimates, highlighting ongoing challenges for the company.
- Market Sentiment: Over the past month, Pfizer's stock has declined by 5.2%, contrasting sharply with peers like Eli Lilly and Merck, which reported revenue growth of 55.5% and 4.9%, respectively, indicating Pfizer's competitive disadvantages.
- Analyst Expectations: With an average analyst price target of $29.00 against a current share price of $26.38, there is a cautious outlook on Pfizer's future performance, especially as most analysts have revised their revenue estimates downward.
See More
PayPal and Anheuser-Busch Beat Earnings Expectations
- PayPal Earnings Surprise: PayPal reported first-quarter earnings of $1.34 per share, exceeding analyst expectations of $1.27, with revenues of $8.35 billion surpassing the $8.05 billion forecast, indicating strong performance in the payments sector that could drive stock price increases.
- Anheuser-Busch Strong Growth: Anheuser-Busch reported earnings of $0.97 per share, beating the expected $0.89, with revenues of $15.27 billion significantly above the $14.87 billion forecast, demonstrating sustained competitiveness in the beer market that may attract more investor interest.
- Pfizer Exceeds Expectations: Pfizer's first-quarter earnings came in at $0.75 per share, above the $0.72 expected, with revenues of $14.45 billion, reflecting robust growth in the pharmaceutical sector that could enhance market confidence in its future products.
- Pinterest Optimistic Revenue Guidance: Pinterest's second-quarter revenue guidance of $1.13 billion to $1.15 billion exceeded the $1.11 billion expected, with first-quarter adjusted earnings of $0.27 per share and revenues of $1.01 billion, showcasing strong growth potential in the social media space that is likely to improve market perceptions of its long-term value.
See More
Pfizer Q1 Earnings Exceed Expectations
- Strong Performance: Pfizer reported adjusted earnings per share of 75 cents for Q1, surpassing the expected 72 cents, with revenue of $14.45 billion reflecting a 5% year-over-year increase, demonstrating robust market performance driven by both new and established products.
- Growth in New Products: The company saw a 22% operational growth in recently launched and acquired products, with the targeted cancer drug Padcev generating $591 million in revenue, a 39% increase from the previous year, exceeding analyst expectations of $542.3 million, indicating a strong return on investment in innovative therapies.
- Decline in Vaccine Sales: Despite the Covid vaccine and Paxlovid generating only $232 million and $186 million in sales, down 59% and 62% year-over-year respectively, Pfizer offset this impact with strong performance from established drugs like Eliquis, which generated $2.17 billion, a 13% increase.
- Stable Long-term Outlook: Pfizer reaffirmed its 2026 outlook, expecting adjusted earnings per share between $2.80 and $3.00 and revenue between $59.5 billion and $62.5 billion, reflecting confidence in navigating challenges from declining Covid product sales and increased market competition.
See More
Pfizer Reports Strong Q1 Earnings, Reaffirms 2026 Outlook
- Earnings Beat: Pfizer's adjusted earnings per share for Q1 reached 75 cents, exceeding the expected 72 cents, reflecting strong performance in newly launched and acquired products, which bolsters investor confidence.
- Revenue Growth: The company reported Q1 revenue of $14.45 billion, surpassing Wall Street's expectation of $13.79 billion, indicating significant growth in its new product offerings and acquisitions, further solidifying its market position.
- Strategic Acquisition: Pfizer's recent $10 billion acquisition of obesity biotech Metsera aims to diversify its product line to offset declining COVID product sales, demonstrating the company's strategic focus on future growth.
- R&D Focus: Pfizer is prioritizing several key data releases this year, including late-stage trial results for an experimental targeted drug in lung cancer, which is expected to drive new growth opportunities for its product pipeline.
See More
BioNTech to Close Sites Affecting 1,860 Jobs and Buy Back $1 Billion in Shares
- Job Cuts and Site Closures: BioNTech announced the closure of multiple sites in Idar-Oberstein, Marburg, and Tuebingen in Germany, as well as in Singapore, affecting up to 1,860 jobs, reflecting a strategic shift following the transfer of COVID-19 vaccine production to partner Pfizer.
- Executive Departures Impact: The departure of the two co-founders and key executives by year-end to focus on new treatments may impact the company's innovation capacity and market competitiveness, particularly in the vaccine sector.
- Cost-Cutting Initiatives: BioNTech plans to implement gradual cost reductions, potentially achieving annual savings of about €500 million by 2029, aimed at improving financial health amid reported net losses.
- Share Buyback Program: The company announced a share buyback of up to $1 billion over the next 12 months to bolster shareholder confidence and enhance stock prices, despite reporting a net loss of €532 million in the first quarter, indicating current financial pressures.
See More
Pfizer's Q1 Earnings Outlook Shows Optimism
- Optimistic Earnings Outlook: Pfizer is expected to exceed market expectations in its Q1 earnings report, with analysts expressing optimism about its robust product pipeline, particularly in the obesity treatment sector, which could drive future revenue growth.
- Pipeline Potential Analysis: The progress in Pfizer's obesity pipeline has garnered attention, with analysts believing that success in this area will provide new revenue streams and further solidify the company's leadership position in the pharmaceutical industry.
- Positive Market Reaction: Investors are optimistic about Pfizer's prospects, anticipating that the company will leverage continuous innovation and strong R&D capabilities to navigate market challenges, thereby enhancing shareholder value.
- Guidance Focus: Pfizer will provide future performance guidance in its earnings report, and the market will closely monitor its outlook for overall performance in 2023 to assess the company's strategic positioning in the competitive pharmaceutical landscape.
See More
